Delivery Order 36C24822D0086-36C24826N0510
Award Date 8/1/26
Potential Completion Date 7/31/27
Potential Value $120K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Redwood City, CA 94065, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, through Veterans Integrated Service Network 8, awarded a delivery order valued at $46,000 to Karius, Inc. for the provision of next-generation sequencing (NGS) testing services. This delivery order, effective through July 31, 2025, represents the third year of testing delivery under a firm fixed-price contract structure with no set-aside designation. Karius, Inc., headquartered in Redwood City, California, is a specialized life sciences company focused on...
- Karius, Inc. has been awarded a $22,000 delivery order by Veterans Integrated Service Network 17 (VISN 17), a civilian agency within the Department of Veterans Affairs, for its Karius Next Generation Sequencing Test. The contract, issued on April 1, 2026, with an ultimate completion date of March 31, 2027, represents a firm fixed-price delivery order without a set-aside designation. The place of performance is located in Redwood City, California, where Karius, Inc. maintains its headquarters....
- The U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 8 has awarded Karius, Inc. a firm-fixed-price delivery order contract for its Karius Next Generation Sequencing (NGS) diagnostic test. The contract has a ceiling value of $60,000 and a performance period from August 1, 2023 to July 31, 2024. This award is part of a larger $600,000 Indefinite Delivery Contract (IDC) that Karius holds with the VA VHA, which has an ultimate completion date of July 31, 2027. The...
- On April 1, 2025, the Department of Veterans Affairs, Veterans Integrated Service Network 17, awarded a delivery order valued at $22,000 to Karius, Inc. under contract 36C25725D0031 (Order #36C25725N0219). This firm fixed-price delivery order, with an ultimate completion date of March 31, 2026, represents performance at the contractor's location in Harlingen, Texas. The award was issued without set-aside designation and leverages Karius, Inc.'s specialized capabilities in next-generation...
- This contract was awarded by the National Institutes of Health (NIH) Clinical Center to Karius, Inc., a life sciences company specializing in diagnostic testing for infectious diseases. The contract, valued at $80,000.00, is for the provision of molecular diagnostic testing services using Karius' liquid biopsy technology to rapidly screen patients for various pathogens. The testing services will be delivered within 3-4 days of specimen receipt. This is a firm fixed-price purchase order...
- This is a firm fixed price purchase order awarded by the Defense Health Agency (DHA) to Karius, Inc. for quantitative next-generation sequencing testing services. The $240,000 contract supports DHA programs through September 2023 and leverages Karius' expertise in genomic sequencing to rapidly screen patients for various pathogens. This is a sole source award, as Karius is the only commercial laboratory capable of providing the requested cell-free DNA testing from plasma samples with 24-72...
- This is a federal contract award to Karius, Inc., a life sciences company specializing in next-generation sequencing (NGS) and molecular diagnostic testing services. The contract, awarded by the U.S. Department of Veterans Affairs (VA), is an Indefinite Delivery Contract (IDC) valued at up to $120,000,000. Under this IDC, the VA can purchase Karius' KARIUS NEXT GENERATION SEQUENCING TEST at $2,000 per test, with Karius identified as the sole responsible source. The contract has a period of...
- The Department of the Navy Bureau of Medicine and Surgery awarded a $140,000 firm fixed price purchase order to Karius, Inc. for the provision of 70 quantitative next generation sequencing tests. This award is not associated with a larger contract vehicle and does not have a set-aside designation. Karius, Inc. is a life sciences company focused on diagnostic testing for infectious diseases. The purchase order supports Department of Defense programs through September 2027 and leverages Karius'...
- The Defense Health Agency awarded a purchase order to Karius, Inc. for quantitative next-generation sequencing testing valued at $164,000 on October 1, 2023, with performance at Naval Medical Center San Diego, San Diego, California and completion by September 30, 2027. No set-aside was used. The order procures NGS laboratory testing services for the Naval Medical Center San Diego Laboratory Department, supporting infectious disease detection and pathogen identification through metagenomic...
- The Defense Health Agency (DOD) awarded a $250,000 firm fixed price purchase order to Karius, Inc., doing business as Karius Inc., located in San Diego, California. The contract is for Quantitative Next-Gen Sequencing Testing Services and has a period of performance from October 1, 2022 through September 30, 2023. Karius provides genomic sequencing and bioinformatics analysis services to identify pathogens and monitor antimicrobial resistance. No applicable subcontractors were identified in...
- 36C24822D0086Indefinite Delivery Contract
- 36C24822D0086-36C24826N0510Delivery Order
Veterans Integrated Service Network 8 issued a delivery order to Karius, Inc. on August 1, 2026, for next-generation sequencing diagnostic testing services at $2,000 per test, with a ceiling value of $120,000 and an ultimate completion date of July 31, 2027. Place of performance is Redwood City, CA. The order is firm fixed price with no set-aside. Karius supplies metagenomic sequencing of microbial cell-free DNA and RNA for infectious disease detection and antimicrobial resistance monitoring from blood specimens.
Generated 7/16/26, 9:56 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $120.0k | 7/14/26 |